[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Manni Huang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100646933","adjuvant-moderately-hypofractionated-intensity-modulated-radiotherapy-for-cervical-cancer-100646933",false,"NCT07684508","Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Cervical Cancer","Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Postoperative Cervical Cancer (AMICA-CC) : a Prospective, Multicenter, Phase II Trial","Inclusion Criteria:\n\n* ECOG performance status 0 or 1;\n* Histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;\n* Status post radical hysterectomy with pelvic lymph node dissection with or without para-aortic lymph node dissection, and postoperative radiotherapy initiated within 3 months;\n* For squamous cell carcinoma: meeting Sedlis criteria; for adenocarcinoma and adenosquamous carcinoma: meeting the \"four-factor model\";\n* Bone marrow function: white blood cell (WBC) count ≥3.0×10⁹\u002FL, neutrophil count (NEUT) ≥1.5×10⁹\u002FL, platelet count (PLT) ≥80×10⁹\u002FL, hemoglobin (Hb) ≥90 g\u002FL; renal function: normal or serum creatinine (SCr) ≤1.5×upper limit of normal (ULN) or creatinine clearance ≥50 ml\u002Fmin; hepatic function: total bilirubin (TBIL) ≤1.5×ULN, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5×ULN;\n* Voluntarily signed the informed consent form prior to study enrollment.\n\nExclusion Criteria:\n\n* History of active malignant tumor within 3 years prior to initial treatment（except for the cervical cancer）and any locally curable tumors treated with radical therapy;\n* Any high-risk factor confirmed by postoperative pathology: positive lymph node metastasis, positive parametrial invasion, or positive resection margin;\n* History of neoadjuvant therapy prior to enrollment;\n* Local recurrence or distant metastasis prior to enrollment;\n* Postoperative intestinal obstruction or intestinal adhesion;\n* Severe cardiac, cerebral, hepatic, or renal disorders;\n* Long-term immunocompromised state;\n* Pregnant or lactating females;\n* Premature discontinuation of treatment for any reason;\n* Poor compliance, unwillingness to participate, or inability to cooperate with follow-up;\n* Any other conditions deemed unsuitable for this trial by the investigator.","FEMALE","18 Years","75 Years",{"count":20,"type":21},154,"ESTIMATED","INTERVENTIONAL",[24],"NA","To investigate the safety and efficacy of moderately hypofractionated intensity-modulated radiotherapy in the treatment of postoperative cervical cancer",[27,28,29],"Hypofractionated Radiotherapy","Intensity-modulated Radiotherapy","Cervical Cancers","RECRUITING","2026-08-03",{"date":33,"type":34},"2026-08-05","ACTUAL",{"date":36,"type":34},"2026-07-10",{"date":38,"type":21},"2030-12-30",{"name":40,"class":41},"Manni Huang","OTHER",2,""]